Trends in RA patients’ adherence to subcutaneous anti-TNF therapies and costs
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To examine adherence to adalimumab (ADA) and etanercept (ETA) and health care costs in rheumatoid arthritis (RA) patients, and to explore the association between adherence, utilization and costs. RESEARCH DESIGN AND METHODS: Using administrative claims data from a large managed health care plan, RA patients treated with etanercept or adalimumab during the period from 01/01/2005 through 12/31/2005 were identified. The first dispensing date was defined as the index date. Patient adherence and costs were assessed during the 1 year post-index period. MAIN OUTCOME MEASURES: Nonadherence (medication possession ratio <80%) was modeled using logistic regression. Hazard ratios (HR) comparing time to discontinuation were estimated using Cox proportional hazard (PH) models. Propensity score matching with multivariate generalized linear modeling adjustment was done to assess cost difference between ADA and ETA. RESULTS: Of 3829 eligible RA patients, 1292 (765 existing, 527 naïve) and 2537 (1834 existing, 703 naïve) patients used ADA and ETA, respectively. Compared with ADA users, ETA users had longer average treatment duration (316 vs. 291 days; p < 0.0001). Unadjusted adherence rates for naïve and existing users were 63% and 70% (ADA), and 65% and 73% (ETA). Logistic regression analysis indicated that compared with ETA users, ADA users were more likely to be nonadherent (OR, naïve 1.24; existing; 1.25). Cox PH models indicated that existing ADA users were more likely to discontinue (HR = 1.11; p = 0.06) their medication than existing ETA users. Compared with ADA users, ETA users had significantly lower RA-related pharmacy costs (naïve: $10,892 vs. $12,534, p < 0.01; existing: $12,192 vs. $13,752, p < 0.01) and RA-related total costs (naïve: $11,976.42 vs. $13,511.99, p < 0.05; existing: $14,031 vs. $15,454, p < 0.05). CONCLUSIONS: ETA users had longer treatment duration, were more likely to adhere to their medication regimen and had lower RA-related pharmacy and RA-related total costs compared with ADA users. These findings must be considered within the limitations of this database analysis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
Rizzo, J. A., & Robert Simons, W. (1997) · Clinical Therapeutics · doi:10.1016/s0149-2918(97)80018-5 · Cited by 174
Cited by
van den Bemt, B. J., Zwikker, H. E., & van den Ende, C. H. (2012) · Expert Review of Clinical Immunology · doi:10.1586/eci.12.23 · Cited by 320
Pasma, A., van't Spijker, A., Hazes, J. M. W., Busschbach, J. J. V., & Luime, J. J. (2013) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2012.12.001 · Cited by 155
Achaval, S. D., & Suarez-Almazor, M. E. (2010) · International Journal of Clinical Rheumatology · doi:10.2217/ijr.10.15 · Cited by 90
Predictors of adherence among Alzheimer's disease patients receiving oral therapy
Borah, B., Sacco, P., & Zarotsky, V. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.493788 · Cited by 67
Self-citation
Metadata
- Authors
- Borah, B. J., Huang, X., Zarotsky, V., & Globe, D.
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa Healthcare
- Published
- 2009-04-28
- Volume
- 25
- Issue
- 6
- Pages
- 1365-1377
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W2149553288
- Cited by
- 98
- References
- 2
- FWCI
- 2.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.